Carisma Therapeutics

Historical price data

Carisma Therapeutics is a pioneer in macrophage-based cell therapy, founded as a spin-out from the University of Pennsylvania. Its mission is to develop engineered CAR-Macrophage and CAR-Monocyte therapies to treat solid tumors and other serious diseases by harnessing cells that naturally infiltrate and remodel hostile tissue microenvironments. The company's strategy centers on advancing its lead anti-HER2 candidate, CT-0508, through Phase 1 trials while expanding its modular platform into new targets and indications, supported by experienced leadership and key academic collaborations. Carisma became a public company via a merger in March 2023.

Proprietary platform for engineering Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes (CAR-Mono), designed to leverage the cells' innate ability to infiltrate solid tumors, phagocytose targets, present antigens, and remodel disease microenvironments.

Carisma is a pioneer in CAR-Macrophage therapy with a clear first-mover clinical advantage. It competes with a small number of private myeloid cell therapy biotechs and, more broadly, with other solid tumor-focused cell therapies (CAR-T, CAR-NK, TILs) and targeted biologics. Its key differentiator is the innate biology of macrophages to infiltrate and remodel solid tumor microenvironments.